Monoamine oxidase and α-synuclein as targets in Parkinson’s disease therapy

α-Synuclein as an intrinsically disordered monomer - fact or artefact?

(2013) Eduardo Coelho-Cerqueira et al.   FEBS Journal

Properties of native brain α-synuclein

(2013) Jacqueline Burré et al.   NATURE

Aldehyde dehydrogenase 2 in sporadic Parkinson's disease

(2013) Tanja Maria Michel et al.   PARKINSONISM & RELATED DISORDERS

Dopamine-Mediated Oxidation of Methionine 127 in α-Synuclein Causes Cytotoxicity and Oligomerization of α-Synuclein

(2013) Kazuhiro Nakaso et al.   PLoS One

Multi Target Neuroprotective and Neurorestorative Anti-Parkinson and Anti-Alzheimer Drugs Ladostigil and M30 Derived from Rasagiline

(2013) Moussa B.H. Youdim   Experimental Neurobiology

Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling

(2012) Paul D. Ray et al.   CELLULAR SIGNALLING

α-Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, andEscherichia coliExists Predominantly as Disordered Monomer

(2012) Bruno Fauvet et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Curcumin Prevents Aggregation in α-Synuclein by Increasing Reconfiguration Rate

(2012) Basir Ahmad et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Systematic Mutagenesis of  -Synuclein Reveals Distinct Sequence Requirements for Physiological and Pathological Activities

(2012) J. Burre et al.   JOURNAL OF NEUROSCIENCE

Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients

(2012) Maria Zellner et al.   Journal of Proteomics

A Novel Conjugated Agent between Dopamine and an A2A Adenosine Receptor Antagonist as a Potential Anti-Parkinson Multitarget Approach

(2012) Alessandro Dalpiaz et al.   MOLECULAR PHARMACEUTICS

Vitamins K interact with N-terminus α-synuclein and modulate the protein fibrillization in vitro. Exploring the interaction between quinones and α-synuclein

(2012) Fernanda Luna da Silva et al.   NEUROCHEMISTRY INTERNATIONAL

Molecular insights into human monoamine oxidase (MAO) inhibition by 1,4-naphthoquinone: Evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO

(2011) Eduardo Coelho Cerqueira et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Oxidation of 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopaminergic Metabolite, to a Semiquinone Radical and anortho-Quinone

(2011) David G. Anderson et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Evaluation of the oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to toxic pyridinium cations by monoamine oxidase (MAO) enzymes and its use to search for new MAO inhibitors and protective agents

(2011) Tomás Herraiz   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Flavonoids and the CNS

(2011) Anna Jäger et al.   MOLECULES

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

(2011) Tim Bartels et al.   NATURE

Effect of melatonin on α-synuclein self-assembly and cytotoxicity

(2011) Kenjiro Ono et al.   NEUROBIOLOGY OF AGING

Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death

(2011) Laura A. Volpicelli-Daley et al.   NEURON

Effect of quercetin and glucuronide metabolites on the monoamine oxidase-A reaction in mouse brain mitochondria

(2011) Saki Yoshino et al.   NUTRITION

Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism

(2011) Zhaohui Liu et al.   PHARMACOLOGICAL RESEARCH

In vivo demonstration that  -synuclein oligomers are toxic

(2011) B. Winner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Curcumin reduces α-synuclein induced cytotoxicity in Parkinson's disease cell model

(2010) Min S Wang et al.   BMC NEUROSCIENCE

REVIEW: Curcumin and Alzheimer's Disease

(2010) Tsuyoshi Hamaguchi et al.   CNS Neuroscience & Therapeutics

Entacapone and Tolcapone, Two CatecholO-Methyltransferase Inhibitors, Block Fibril Formation of α-Synuclein and β-Amyloid and Protect against Amyloid-induced Toxicity

(2010) Saviana Di Giovanni et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Anti-Parkinsonian Drug Selegiline Delays the Nucleation Phase of α-Synuclein Aggregation Leading to the Formation of Nontoxic Species

(2010) Carolina A. Braga et al.   JOURNAL OF MOLECULAR BIOLOGY

Dietary inhibitors of monoamine oxidase A

(2010) Sarah E. Dixon Clarke et al.   JOURNAL OF NEURAL TRANSMISSION

 -Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro

(2010) J. Burre et al.   SCIENCE

Pre-fibrillar α-synuclein variants with impaired β-structure increase neurotoxicity in Parkinson's disease models

(2009) Damla Pinar Karpinar et al.   EMBO JOURNAL

Formation of dopamine-mediated α-synuclein-soluble oligomers requires methionine oxidation

(2009) Su Ling Leong et al.   FREE RADICAL BIOLOGY AND MEDICINE

Conversion of Wild-type α-Synuclein into Mutant-type Fibrils and Its Propagation in the Presence of A30P Mutant

(2009) Motokuni Yonetani et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Curcumin reverses impaired cognition and neuronal plasticity induced by chronic stress

(2009) Ying Xu et al.   NEUROPHARMACOLOGY

Restoration of Nigrostriatal Dopamine Neurons in Post-MPTP Treatment by the Novel Multifunctional Brain-Permeable Iron Chelator-Monoamine Oxidase Inhibitor Drug, M30

(2009) Shunit Gal et al.   NEUROTOXICITY RESEARCH

Curcumin inhibits aggregation of α-synuclein

(2008) Neeraj Pandey et al.   ACTA NEUROPATHOLOGICA

Phosphorylation of tau and α-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer’s disease, and in Parkinson’s disease and related α-synucleinopathies

(2008) G. Muntané et al.   NEUROSCIENCE

Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson’s disease induced by MPTP neurodegeneration in mice

(2008) A. Rajeswari et al.   INFLAMMOPHARMACOLOGY